DiFusion Receives New Patent

DiFusion Technologies announced the issuance of a new US Patent 12,178,936 B2 “Medical Implants and Methods of Manufacture.” The new patent encompasses four methods to manufacture ZFUZE, a proprietary therapeutic, anti-inflammatory, osseoconductive, load-bearing biomaterial for orthopedic implants. 

ZFUZE is the first FDA-cleared advanced biomaterial for spinal implants that is proven to create a highly favorable cellular and immunologic response post-surgery. In a recent 75-patient retrospective study, ZFUZE posted a 93.4% lumbar spinal fusion rate at 6 months while similar competitive studies demonstrate average lumbar fusion rates of 68% at 12 months.

“This new patent firmly protects our ZFUZE FDA Master File for another 17 years. ZFUZE is the only FDA cleared immuno-modulating biomaterial currently available to patients’ surgeons and hospitals,” DiFusion Founder and CEO Derrick Johns. “Building a FDA Master File is a long, arduous and expensive process that larger orthopedic companies are not scientifically equipped to execute.”